Reduces the incidence of hospital and healthcare-facility acquired infections
INTRODUCTION REDUCE S THE INCIDENCE OF HOSPITAL AND HE ALTHC ARE-FACILIT Y ACQUIRED INFEC TIONS.
Immediate ef f icac y Zylas t kill s 25 FDA-specif ied challenge microorganisms within 15 seconds
Proven 6-hour persistence Zylas t kill s microbes for six hours af ter a single application
Broad-spec trum ef f icac y against bac teria, fungi, and viruses Zylas t protec t s agains t bac teria, fungi, and viruses to help reduce the incidence of illness, including MRSA , vancomycin-resis tant enterococcus, carbapenem-resis tant enterobac teriaceae, candida albicans, norovirus, , HIV, rhinovirus, rotavirus, enterovirus, and inf luenza.
Increased compliance among health care personnel Benzethonium chloride (BZ T), the ac tive ingredient in Zylas t produc t s, has been shown to increase dermal mois ture and produce no skin irritation, thereby increasing compliance with hand hygiene.
PRODUCT SUMMARY Designed to prevent infec tion in hospit al s and nur sing homes, Zyla s t produc t s utilize a unique antimicrobial technolog y that not only kill s on cont ac t , but is per sis tent for six hour s . The core of the patented technolog y lies in the s ynergis tic combination of antimicrobial agent s, including benzethonium chloride (BZ T), and a revolutionar y formulation that keeps the produc t on the skin. Currently available Zyla s t produc t s include an alcohol-ba sed Antiseptic , a mois turizing Antiseptic Lotion, a Surgical Scrub, and a Foaming Hand Cleanser. Nine clinical s tudies a s well a s well a s s tudies agains t drug-resis t ant bac teria and viruses have been conduc ted with Zyla s t produc t s and it s ac tive ingredient s . Additional tes ting ha s shown that these produc t s, unlike other antimicrobial s tes ted, do not irrit ate the skin with repeated use.
Immediate Ef f icac y Against Bac teria: Zy l a s t Ant is ept ic and Ant is ept ic Lot ion have been shown to k ill more t han 9 9.9 9% of 2 5 FDA-specif ied challenge microor g anims , including E . coli, S . aureus , Acinetobac ter, and ot her common pat hogens .1
Immediate Ef f icac y Against Viruses: Zy l a s t Ant is ept ic ha s been shown to be more t han 100 t ime s more ef fec t ive ag ains t t he Norovirus t han alcohol s anit izer s alone2 The ac t ive ing redient of Zy l a s t k illed more t han 9 9% of Inf luenz ae, Rhinovirus , Rot avirus , Herpe s Simplex , and HIV wit hin 30 s econds . 3,4, 5
Persistence: The Center for Dis ea s e Cont rol recommends t hat a hand s anit izer should be “ f a s t-ac t ing , broad spec t rum, and, if pos sible, per sis tent .�6 St andard alcohol s anit izer s have no per sis tence – once t he alcohol ev apor ate s , af ter 15 s econds , t he hands c an immediately be re - cont aminated. Zy l a s t produc t s are per sis tent for si x hour s , cont inuing to k ill more t han 9 9.9% of pat hogens t hat come into cont ac t wit h t he sk in. Even if an employee may not be able to comply wit h hand hy g iene g uideline s , t he per sis tence of Zy l a s t reduce s t r ansmis sion of microor g anisms .7
Zylast provides protection to a broad-spectrum efficacy against bacteria, fungi, and viruses such as MRSA and HIV.
BASIC SCIENCE EVIDENCE Zylast Antiseptic Kill s Norovirus – The Zyla s t technolog y wa s shown to kill 99.97 % of a surrog ate Norovirus on cont ac t , more than 100 times more potent than traditional alcohol s anitizer s .1
Zylast Antiseptic and Zylast Antiseptic Lotion Kill Over 99.7% of FDA-Specif ied Challenge Microorganisms – The Zyla s t Antiseptic and Zyla s t Antiseptic Lotion were tes ted ag ains t 2 5 FDA-specif ied challenge microor g anisms . The Zyla s t Antiseptic killed 99.9% of all or g anisms and Zyla s t Antiseptic Lotion killed more than 99.7 % of all or g anisms on cont ac t . The Zyla s t Antiseptic Lotion wa s shown to be the only non-alcohol ba sed produc t to have equivalent or superior kill to an alcohol-ba sed s anitizer. 2
Acinetobac ter Baumanii Doesn’t Develop Bac terial Resistance Against BZT, the Ac tive Ingredient in Zylast Produc t s – Researcher s demons trated that A . baumanii, an impor t ant reference s train of bac teria , does not develop resis t ance to BZ T. 3
Zylast Foaming Soap Demonstrates Persistence of Ef fec t Superior to Other Soap Produc t s – The Zyla s t Foaming Soap wa s compared ag ains t other s t andard soaps , both antimicrobial and plain. Tes ting wa s per formed ag ains t E. coli. Zyla s t Foaming Soap wa s shown to signif icantly outper form Ly sol , CHG , and Lifebuoy soaps , s till killing 100% of the transient bac teria 1 hour and 82% of the transient bac teria six hour s af ter the soap wa s applied and wa shed of f.4
Zylast Antiseptic , Zylast Antiseptic Lotion, and Zylast Foaming Soap Demonstrate Persistent Ef f icac y Against MRSA – The Zyla s t produc t s were tes ted in vitro for per sis tent ef f icac y ag ains t MR SA . All three produc t s tes ted showed the abilit y to kill more than 90% of the drug-resis t ant bac teria that came in cont ac t with skin at 2 minutes and 1 hour af ter application, with ef f icac y level s at 6 hour s above 80% for the leave-on produc t s . 5
Ac tive Ingredient s in Zylast Outper form Other Competitive Produc t s – Using an in vitro skin model , the ac tive ingredient s in the Zyla s t Antiseptic were s tudied and compared ag ains t leading alcohol-ba sed hand s anitizer s . The produc t with the combination of ethanol and BZ T signif icantly outper formed ever y produc t on the market ag ains t transient bac teria , both gram-positive and gram-neg ative.6,7. 1. C zer winski SE, Cozean J, An evaluation of a Hand S anitiser Produc t to Reduce Norovirus Cros s Infec tion, British Global Travel Health A s sociation Journal , 2012 20: 42-4 6. 2.
Czerwinski SE, Cozean J, Cozean C. Novel water-based antiseptic lotion demonstrates rapid, broad-spectrum kill compared with alcohol antiseptic. J Infect Public Health. 2014 MayJun;7(3):199-204.
3.
Kawamura-Sato K, Wachino J, Kondo T, Ito H, Arakawa Y. Reduction of disinfectant bactericidal activities in clinically isolated Acinetobacter species in the presence of organic material. J Antimicrob Chemother. 2008 Mar;61(3):568-576.
4. Haskins Laboratory, Pace University. Extended Protection Testing of ohe Zylast Products. May 24, 2013. 5.
Morada, et al Not sure if Morada et al ever actually published)
6. Shintre MS, Gaonkar TA, Modak SM. Efficacy of an alcohol-based healthcare hand rub containing synergistic combination of farnesol and benzethonium chloride. Int J Hyg Environ Health. 2006 Sep;209(5):477-487. 7.
Shintre MS, Gaonkar TA, Modak SM. Evaluation of an alcohol-based surgical hand disinfectant containing a synergistic combination of farnesol and benzethonium chloride for immediate and persistent activity against resident hand flora of volunteers and with a novel in vitro pig skin model. Infect Control Hosp Epidemiol. 2007 Feb;28(2):191-197.
15
Zylast kills 25 FDA-specified challenge microorganisms within 15 seconds
CLINICAL EVIDENCE REDUCE S THE INCIDENCE OF HOSPITAL AND HE ALTHC ARE-FACILIT Y ACQUIRED INFEC TIONS.
Clinical Evaluation for Persistence of Antimicrobial Ef f icac y of Zylast Antiseptic – This randomized clinical s tudy evaluated the persis tence of the Zylas t Antiseptic. The Zylas t Antiseptic was applied to the skin of volunteers, and allowed to dr y. Af ter various periods of time (20 minutes, 1 hour, and 6 hours), the treated skin was challenged with an inoculum of E. coli. The Zylas t Antiseptic killed more than 99.9% of transient germs at all timepoint s, including six hours af ter application.1
Clinical Evaluation of Antimicrobial Ef f icac y of Zylast Antiseptic and Antiseptic Lotion – The Zylas t Antiseptic and Antiseptic Lotion were tes ted in a randomized clinical s tudy according to the s tandard EN1500 protocol. Both produc t s signif icantly exceeded the ef f icac y of an alcohol reference produc t , and the Antiseptic Lotion was the f irs t non-alcohol produc t to pass this tes ting. 2
Clinical Trial in Hospital – In a randomized, crossover s tudy of more than 6,000 patient-days across three wards, Zylas t was shown to reduce Hospital Acquired Infec tions (HAIs) by 23.1% over hand washing alone, with universal acceptance by healthcare workers and s taf f. 3 1. BioScience Laboratories. Clinical evaluation of the persis tent antimicrobial ef f icac y of three tes t produc t s and one control produc t based on A STM e2752-10. Final repor t # 130762-150.01 B. Oc tober 30, 2014.
2. (Canew Testing, 2013).(Cozean and McNichol, 2103 ¬ Cannot find this reference) 3. Kampiatu P, Cozean J. A controlled, crossover study of a persistent antiseptic to reduce hospital-acquired infection. Afr J Infect Dis. 2015;9(1):6-9
Protection Can Start Now. To Place An Order Please direct all emails to: Apoth Distribution Email: mrgreen@apothfrd.com